REGENER-EYES®

Regener-Eyes® Government Mission Statement:

Our mission is to develop innovative, pharmacologic solutions that empower physicians and clinicians to provide the best in care to our military service members and veterans.

Regener-Eyes® Government Mission Objective:

Our mission is to help our veterans and military service members gain easy and affordable access to life-changing medicines. We accomplish this by making Regener-Eyes® available to the VA, DOD, FEMA, and other government agencies through special contracting vehicles, the VANF and Tricare formularies, our pharmaceutical and SDVOSB Distributor partners, and through other federal procurement pathways.

Regener-Eyes® is Proudly:

  • Made and Manufactured in the USA, FDA Registered and Compliant
  • Trade Agreement Act Compliant
  • Berry Amendment Compliant
  • Buy American Act Compliant
  • Commonly Used and Recommended Within The VA Healthcare Network, The Military Health System, and The Kaiser Permanente Health Care System

Regener-Eyes® Safety:

Regener-Eyes® offers a safe and effective solution as a more affordable option.

POTENTIAL COST SAVINGS

EXPLORING REGENER-EYES MECHANISM OF ACTION

Regener-Eyes® Tonicity Solution™ employs patented technology to combat dry eye-triggering hyperosmolarity

Download Capabilities PDF

GOVERNMENT POC

Corporate Data

CAGE: 79YW0 | UEI: N2ZTM3FCKHN5
Work Area: Nationwide
Gov. Bus. POC: Valentino Pine, Director of Government Relations
Phone: (813) 901-4064
E-Mail: Valentino@RegenerativePlant.org
Website: www.RegenerEyes.com
Socio-Economic Status: Small Business Enterprise (SBE)
Primary NAICS: 325412: Pharmaceutical Preparation Manufacturing

Distributor Contact Info

CAGE: 1TAP7 | UEI: VSSNJEFMPLB3VA FSS 651b
Contract #: 36F79719D0161
Gov. Bus. POC: Samir Patel, President
Gov. POC Email: Samir@MarlexPharm.com
Phone: (888) 582-1953
Fax: (302) 898-1609
E-Mail: CustomerService@MarlexPharm.com
Website: www.MarlexPharm.com

NAICS & PSC Codes

NAICS Codes:
Primary 325412: Pharmaceutical Preparation Manufacturing
339115: Ophthalmic Goods Manufacturing
339113: Surgical Appliance & Supplies Manufacturing
541690: Other Scientific & Technical Consulting Services
541714: Research & Development in Biotechnology
541990: All Other Professional, Scientific & Technical Services
541715: R&D, Physical, Engineering & Life Sciences
(Non-Defense Applications)
PSC Codes:
6505: Drugs & Biologicals
6540: Ophthalmic Instruments, Equipment & Supplies
NDC:
82305-0003-02 Regener-Eyes Pro
82305-0006-02 Regener-Eyes Lite
Mckesson Item Number:
2823243 Regener-Eyes Pro
2823359 Regener-Eyes Lite

CORE COMPETENCIES

  • Regener-Eyes® Ophthalmic Solution helps increase lubrication and hydration of the corneal surface. This helps to relieve dryness of the eye.
  • Regener-Eyes® Ophthalmic Solution has an excellent safety profile.
  • Regener-Eyes® is non-steroidal. It helps to protect and relieve dryness of the eye.
  • Each batch of Regener-Eyes® is tested to ensure quality, sterility, and safety.
  • Regener-Eyes® Ophthalmic Solution, can be stored at room temperature until use. Once opened, each bottle can be stored at room temperature and used within 90 days.
  • Regener-Eyes® Ophthalmic Solution, has a shelf life of two (2) years when stored at room temperature.

PAST PERFORMANCE

  • Department of Veterans Affairs
    Strategic Acquisition Center Contract

    Contract #: 36C106
    Date(s): 2018-Present | Type: IDC
    Details: Drugs & Biologics
    Department of Veterans Affairs
    Date(s): 2023-Present | Value: $40,000
    Details: Provided Amniotic Membrane and Regener-Eyes LITE to Network Contracting Office 19 & 16 through the VANF.
  • Department of Defense
    Date(s): 2023-Present | Role: Subcontractor
    Details: Provided Regener-Eyes LITE through distributor Marlex Pharmaceuticals to DoD prime vendor: McKesson
    Kaiser Permanente
    Date(s): 2022-Present
    Details: Provided Regener-Eyes LITE & Regener-Eyes Pro to Kaiser Permanente’s National Hospital Network

JAMES LEWIS, MD

Board Certified Ophthalmologist, Doctor James S. Lewis, Director of Cataract, LASIK and Corneal Surgery (Pennsylvania College of Optometry, Salus University) shares his experience using Regener-Eyes® in his clinical practice.

DÁMARIS RAYMONDI, OD, FAAO

Dr. Damaris Raymondi is the New York State Young Optometrist of the Year 2023. She received her Doctor of Optometry degree from the SUNY College of Optometry in 2015. She splits her time between NYC Health + Hospitals/Metropolitan and her practice Sur Eye Care. Her focus is on pediatrics and ocular disease.

Optometry Times: Helping Dry Eye Associated with Sjögren's Syndrome: A Case Study By Dámaris Raymondi, OD, FAAO

Click Here to Read
Read White Paper

The Molecular Mechanisms Responsible for Tear Hyperosmolarity-Induced Pathological Changes in the Eyes of Dry Eye Disease Patients

This research delves into the molecular mechanisms underlying Tear Hyperosmolarity (THO) in Dry Eye Disease (DED). Driven by a collaborative effort between scientists and healthcare experts, spearheaded by Dr. C. Randall Harrell, it introduces a groundbreaking approach to treating dry eye by elucidating the fundamental causes of the condition. The paper highlights THO as a key player in the onset and progression of DED, contributing to discomfort, inflammation, and eye damage. The findings propose innovative solutions, such as personalized eye drops, aimed at restoring tear composition. Additionally, the research advocates for exploring hypo-osmotic eye drops and NF-κB inhibitors to enhance the effectiveness of DED treatment.
READ WHITE PAPER

Regener-Eyes® Ophthalmic Solution: A New Therapeutic Agent to Relieve Dryness of the Eye for Tear Hyperosmolarity-Induced Pathological Changes in the Eyes of Patients Suffering From Dry Eye Discomfort

Regener-Eyes® is an FDA-regulated OTC drug product designed to relieve dryness of the eye, with its Founder, CEO, and Chief Medical Officer, Dr. C. Randall Harrell, publishing a peer-reviewed scientific white paper on the ophthalmic solution. The patented technology targets hyperosmolarity as a cause of dry eyes, offering a hypotonic solution to slow down the dry eye cycle and promote homeostasis for corneal surface health. Dr. Harrell, with over 40 years of experience, has been a pioneer in medicine, contributing to numerous developments and therapies, and even receiving a Nobel Peace Prize nomination for medical missionary work.